Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 6/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.36 |
| ▸ | SCN4A | P35499 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 3/20 | 0.32 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31745504 | 0.89 | BTK (0.34) | BTKCHEK2ADAMTS4 | |
| SCHEMBL31745484 | 0.82 | BTK (0.41) | BTK | |
| SCHEMBL30791515 | 0.80 | BTK (0.41) | BTKCHEK2SCN4ARAB9AHTT | |
| SCHEMBL30736084 | 0.73 | ALDH1A1 (0.41) | BTKRAB9AALDH1A1LMNAPKM | |
| SCHEMBL31745551 | 0.71 | BTK (0.38) | BTKHTTMAPTKDM4E | |
| SCHEMBL31745492 | 0.70 | GRM5 (0.36) | BTKADAMTS4 | |
| SCHEMBL31360346 | 0.70 | BTK (0.38) | BTKHTTMAPTKDM4E | |
| SCHEMBL31745500 | 0.69 | TGFBR1 (0.33) | BTKADAMTS4 | |
| SCHEMBL31745478 | 0.68 | MEN1 (0.37) | BTKMAPTADAMTS4 | |
| SCHEMBL30791511 | 0.68 | BTK (0.40) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382297-A1 | INHIBITORS OF FGFR2 AND FGFR3 AND USES THEREOF | INSILICO MEDICINE IP LTD (HK) | 2025-12-18 | — | — | US | disclosed |
| EP-4547669-A1 | INHIBITORS OF FGFR2 AND FGFR3 AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2025-05-07 | — | — | EP | disclosed |
| CN-119451964-A | FGFR2 and FGFR3 inhibitors and uses thereof | 英矽智能科技知识产权有限公司 | 2025-02-14 | — | — | CN | disclosed |
| WO-2024002157-A1 | INHIBITORS OF FGFR2 AND FGFR3 AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2024-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382297-A1 | INHIBITORS OF FGFR2 AND FGFR3 AND USES THEREOF | FGFR3, FGFR2, FGFR1 | BTK 178/4885CHEK2 191/4885SCN4A 4093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.